1. Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study. Issue 6 (June 2021) Authors: Hamadani, Mehdi; Collins, Graham P; Caimi, Paolo F; Samaniego, Felipe; Spira, Alexander; Davies, Andrew; Radford, John; Menne, Tobias; Karnad, Anand; Zain, Jasmine M; Fields, Paul; Havenith, Karin; Cruz, Hans G; He, Shui; Boni, Joseph; Feingold, Jay; Wuerthner, Jens; Horwitz, Steven Journal: Lancet Issue: Volume 8:Issue 6(2021) Page Start: e433 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study. Issue 11 (November 2021) Authors: Querfeld, Christiane; Thompson, John A; Taylor, Matthew H; DeSimone, Jennifer A; Zain, Jasmine M; Shustov, Andrei R; Johns, Carolyn; McCann, Sue; Lin, Gloria H Y; Petrova, Penka S; Uger, Robert A; Molloy, Naomi; Shou, Yaping; Akilov, Oleg E Journal: Lancet Issue: Volume 8:Issue 11(2021) Page Start: e808 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗